Genomic Characterization of de novo Metastatic Breast Cancer.
Ana Christina Garrido-CastroLiam F SpurrMelissa E HughesYvonne Y LiAndrew D CherniackPriti KumariMaxwell R LloydBrittany BychkovskyRomualdo Barroso-SousaSimona Di LascioEsha JainJanet FilesAyesha Mohammed-AbreuMax KrevalinColin MacKichanWilliam T BarryHao GuoDaniel XiaEthan CeramiBarrett J RollinsLaura E MacConaillNeal I LindemanIan E KropBruce E JohnsonNikhil WagleEric P WinerDeborah A DillonNancy U LinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Genomic differences between treatment-naïve dnMBC and primary tumors of patients who developed rMBC may provide insight into mechanisms underlying metastatic potential and differential therapeutic sensitivity in dnMBC. Alterations associated with poor OS in dnMBC highlight the need for novel approaches to overcome potential intrinsic resistance to current treatments.